Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognition

DC-based vaccines that initiate T cell responses are well tolerated and have demonstrated efficacy for tumor immunotherapy, with the potential to be combined with other therapies. Targeting vaccine antigens (Ag) directly to the DCs in vivo is more effective than cell-based therapies in mouse models...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCI Insight
Autors principals: Tullett, Kirsteen M., Leal Rojas, Ingrid M., Minoda, Yoshihito, Tan, Peck S., Zhang, Jian-Guo, Smith, Corey, Khanna, Rajiv, Shortman, Ken, Caminschi, Irina, Lahoud, Mireille H., Radford, Kristen J.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2016
Matèries:
Technical Advance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033826/
https://ncbi.nlm.nih.gov/pubmed/27699265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.87102
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars